Erratum: Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease

University of Groningen

Erratum: Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with

type 2 diabetes and Stages 3b-4 chronic kidney disease

Dekkers, Claire C J; Wheeler, David C; Sjöström, C David; Stefansson, Bergur V; Cain,

Valerie; Heerspink, Hiddo J L

Published in:

Nephrology, Dialysis, Transplantation

DOI:

10.1093/ndt/gfy135

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2018

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Dekkers, C. C. J., Wheeler, D. C., Sjöström, C. D., Stefansson, B. V., Cain, V., & Heerspink, H. J. L.

(2018). Erratum: Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease. Nephrology, Dialysis, Transplantation, 33(7), 1280. https://doi.org/10.1093/ndt/gfy135

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Erratum

Claire C.J. Dekkers, David C. Wheeler, C. David Sjo¨stro¨m, Bergur V. Stefansson, Valerie Cain and

Hiddo J.L. Heerspink

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kid-ney disease, Nephrology Dialysis Transplantation, gfx350, https://doi.org/10.1093/ndt/gfx350

In the above article, the n numbers for the least squares mean values (LSM) reported below figure 2A were incorrect. The num-bers for Week 102 were repeated under the graph rather than displaying the true LSM values, which were 62 for placebo, 55 for dapa-gliflozin 5 mg and 85 for dapadapa-gliflozin 10 mg. The authors apologise for the error which has been corrected.

ERRATUM

VC_{The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA.}

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial

re-use, please contact journals.permissions@oup.com 1280

Nephrol Dial Transplant (2018) 33: 1280 doi: 10.1093/ndt/gfy135

Advance Access publication 11 May 2018